The most commonly reported cardiac adverse events following CDK4/6 inhibitor administration were myocardial infarction (n = 266, 12.9%), followed by cardiac disorder (n = 250, 12.1%) and atrial fibrillation (n = 234, 11.3%). This evidence concerns the gene CDK4 and myocardial infarction.